GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (STU:19X) » Definitions » Cyclically Adjusted Price-to-FCF

Axsome Therapeutics (STU:19X) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Axsome Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Axsome Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Cyclically Adjusted Price-to-FCF Chart

Axsome Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Axsome Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Axsome Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Axsome Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Axsome Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Axsome Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Axsome Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.827/134.9266*134.9266
=-0.827

Current CPI (Mar. 2025) = 134.9266.

Axsome Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.148 100.684 -0.198
201509 -0.097 100.392 -0.130
201512 -0.108 99.792 -0.146
201603 -0.186 100.470 -0.250
201606 -0.248 101.688 -0.329
201609 -0.227 101.861 -0.301
201612 -0.358 101.863 -0.474
201703 -0.318 102.862 -0.417
201706 -0.268 103.349 -0.350
201709 -0.229 104.136 -0.297
201712 -0.219 104.011 -0.284
201803 -0.213 105.290 -0.273
201806 -0.255 106.317 -0.324
201809 -0.193 106.507 -0.244
201812 -0.288 105.998 -0.367
201903 -0.254 107.251 -0.320
201906 -0.227 108.070 -0.283
201909 -0.280 108.329 -0.349
201912 -0.455 108.420 -0.566
202003 -0.569 108.902 -0.705
202006 -0.452 108.767 -0.561
202009 -0.358 109.815 -0.440
202012 -0.453 109.897 -0.556
202103 -0.611 111.754 -0.738
202106 -0.561 114.631 -0.660
202109 -0.610 115.734 -0.711
202112 -0.676 117.630 -0.775
202203 -0.779 121.301 -0.867
202206 -0.818 125.017 -0.883
202209 -0.553 125.227 -0.596
202212 -0.602 125.222 -0.649
202303 -0.126 127.348 -0.133
202306 -1.173 128.729 -1.229
202309 -1.072 129.860 -1.114
202312 -0.588 129.419 -0.613
202403 -1.040 131.776 -1.065
202406 -0.589 132.554 -0.600
202409 -0.350 133.029 -0.355
202412 -0.516 133.157 -0.523
202503 -0.827 134.927 -0.827

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (STU:19X) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Axsome Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
One World Trade Center, 22nd Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Headlines

No Headlines